News Website

IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan

IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer StockTitan

Published: Dec. 10, 2024, 11 a.m.

Read Full Article

Endometrial Cancer Market: Opportunities, Challenges, - openPR

Endometrial Cancer Market: Opportunities, Challenges, openPR

Published: Dec. 10, 2024, 7:16 a.m.

Read Full Article

GSK Korea expands indication for Jemperli in endometrial cancer treatment - KBR

GSK Korea expands indication for Jemperli in endometrial cancer treatment KBR

Published: Dec. 10, 2024, 3:13 a.m.

Read Full Article

A bioinformatics analysis of gene expression in endometrial cancer, endometriosis and obesity.

Endometrial cancer (EC), endometriosis (ENDO), and obesity (OBY) are interconnected conditions in women that may share underlying genetic pathways. This study aimed to identify shared genetic pathways and differential gene …

Published: Dec. 9, 2024, midnight

Read Full Article

Differentially expressed genes endometrial cancer endometriosis gene ontology mutational profile obesity

The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer - Targeted Oncology

The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer Targeted Oncology

Published: Dec. 8, 2024, 5 p.m.

Read Full Article

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - BioSpace

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer BioSpace

Published: Dec. 6, 2024, 8:22 a.m.

Read Full Article

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer - OncLive

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer OncLive

Published: Dec. 5, 2024, 7:04 p.m.

Read Full Article

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - The Malaysian Reserve

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer The Malaysian Reserve

Published: Dec. 5, 2024, 3:36 p.m.

Read Full Article

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - Canada NewsWire

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer Canada NewsWire

Published: Dec. 5, 2024, 2:43 p.m.

Read Full Article

Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” - Oncology News Central

Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” Oncology News Central

Published: Dec. 5, 2024, 12:54 p.m.

Read Full Article

Latest Articles

IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan

Endometrial Cancer Market: Opportunities, Challenges, - openPR

GSK Korea expands indication for Jemperli in endometrial cancer treatment - KBR

A bioinformatics analysis of gene expression in endometrial cancer, endometriosis and obesity.

The Targeted Pulse: Don’t Miss the FDA’s Latest Treatment Decisions and What a Retrospective Study Revealed in Endometrial Cancer - Targeted Oncology

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - BioSpace

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer - OncLive

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - The Malaysian Reserve

Nova Scotia becomes first province to publicly reimburse JEMPERLI for the treatment of patients with advanced or recurrent dMMR/MSI-H endometrial cancer - Canada NewsWire

Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story” - Oncology News Central

Subscribe to Our Newsletter